Pantheon Vision Announces Two Successful Pre-Submission Meetings With the FDA
BALTIMORE--(BUSINESS WIRE)--Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to eliminate corneal blindness, announced today the completion of two successful and productive Pre-Submission meetings with the U.S. Food and Drug Administration (FDA). Pantheon Vision requested these early interactions with the FDA review team to obtain agency guidance on preclinical and clinical work supporting a Premarket Approval (PMA) submission. Corneal blind